Guo, X., Zhang, Y., Wei, X., Lei, H., Wei, Q., Wei, Y., Wu, D., Su, N., Feng, R. (2025). A Phase II study of time-limited treatment with orelabrutinib plus bendamustine and obinutuzumab (OBG) in patients with treatment-Naïve CLL/SLL patients. Blood. https://doi.org/10.1182/blood-2025-7417